BIONET Therapeutics Corp.

As of June 30, 2026, BIONET Therapeutics Corp. carries a market capitalization of 2.52B, placing it among publicly traded companies globally. Its enterprise value stands at 1.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, BIONET Therapeutics Corp. has 70.00M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, BIONET Therapeutics Corp. maintains a current ratio of 16.75, meaning it holds 16.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, BIONET Therapeutics Corp.'s stock has declined approximately 37.91% over the past 52 weeks. The 50-day moving average sits at 34.80, while the 200-day moving average is 41.14.

As of June 30, 2026, BIONET Therapeutics Corp. holds 1.03B in cash and equivalents against 23.95M in total debt, resulting in a net debt position of -31.27M. Total book value stands at 1.19B, with working capital of 1.06B providing operational flexibility.